GlassScriptPhysician profile
Jeffrey Crist
NPI 1255318762
$3,311.16
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $859 · 2021: $1,143 · 2022: $733.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $899.75 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $703.02 | 2020-2021 | |
| Janssen Biotech, INC. | $305.92 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $272.87 | 2019-2022 | |
| Braintree Laboratories, INC. | $243.71 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $222.79 | 2019-2022 | |
| Pfizer INC. | $221.24 | 2019-2021 | |
| Daiichi Sankyo INC. | $117.38 | 2019-2022 | |
| Celgene Corporation | $78.54 | 2022 | |
| Alfasigma USA, INC. | $47.87 | 2022 | |
| Redhill Biopharma INC. | $43.36 | 2020-2021 | |
| Shionogi INC | $40.38 | 2019-2020 | |
| Qol Medical, LLC | $34.62 | 2019 | |
| Ardelyx, INC. | $21.28 | 2022 | |
| Pharmacosmos Therapeutics INC. | $17.98 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $15.38 | 2020 | |
| Ironwood Pharmaceuticals, INC | $13.11 | 2020 | |
| Ucb, INC. | $11.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Crist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.